Doxycycline 7 days
ApprovedSmall molecule
Doxycycline 7 days is one of 56 small molecule programs targeting Scrub Typhus. It is currently in Approved.
3
Indications
5
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
87 competitors in Dermatitis
#DrugCompanyPhaseTrials
1EBGLYSS
Eli LillyPhase 3
Clarinex
OOrganon and Co
Phase 3
Zyrtec
KKenvue Brands
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Xyzal
CChattem
Phase 3
Elidel
BBausch Health Americas, Inc.
Phase 3
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Phase 3
Peridex
MMedline Industries
Phase 3
Panretin
AAdvanz Pharma
Phase 3
Curcumin
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Doxycycline 7 days. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details